ArticleGastroenterology2024
The FOXP3
Article in Gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 33 citations in OpenAlex.
- Unraveling the drug resistance web in IBD: The gut microbiota-immunity-epigenetics axis.Gut microbes · 2026Review
- Disrupting intestinal cell pyroptosis-NETs crosstalk reverse mucosal damage and restore Treg/Th17 equilibrium in ulcerative colitis via a calcium pectate microsphere composite hydrogel.Journal of nanobiotechnology · 2026Article
- Regulatory T cells in cancer and inflammation.Signal transduction and targeted therapy · 2026Review
- Beta-Glucan modulates monocyte plasticity and differentiation capacity to mitigate DSS-induced colitis.eLife · 2026Article
- Next-Generation regulatory T cell therapies: Translational considerations for inflammatory bowel disease.Human immunology · 2026Review
- Spatial transcriptomics atlas of inflammatory bowel disease to guide implementation in research consortiums and clinical trials.Nature communications · 2026Article
- Pathobiont-triggered induction of goblet cell response drives regional susceptibility to inflammatory bowel disease.The Journal of clinical investigation · 2026Article
- Organoid-Immune Co-Cultures: A Next-Generation approach to disease modeling.Molecular biology reports · 2026Review
- Shared genetic architecture between schizophrenia and gastrointestinal diseases: insights from large-scale genome-wide cross-trait analysis.Annals of general psychiatry · 2026Article
- Lacticaseibacillus rhamnosus LRa05 mitigates DSS-Induced colitis via boosting beneficial gut microbiota and facilitating CD4⁺Foxp3⁺ Treg differentiation.BMC microbiology · 2026Article
- Intestinal Stem Cells From Patients With Inflammatory Bowel Disease Retain an Epigenetic Memory of Inflammation.Cellular and molecular gastroenterology and hepatology · 2026Article
- Clinical study on the screening of biomarkers for Crohn's disease based on blood metabolomics.Frontiers in gastroenterology (Lausanne, Switzerland) · 2026Article
- FOXP3 Stability-Adaptation Paradox: Reshaping Treg-Based Therapies for Intestinal Diseases.International journal of biological sciences · 2026Review
- Cellular senescence in Crohn's disease: a double-edged sword in intestinal fibrosis.Frontiers in immunology · 2026Review
- Intrinsic MicroRNA-10a Restricts Regulatory T Cell Suppressive Function and Intestinal Repair by Coordinating Transcriptional, Metabolic, and Epithelial Repair Pathways.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Cellular and molecular mechanisms in the pathogenesis of pouchitis: more than just the microbiota.Gut · 2025Review
- Neuroimmune interactions: The bridge between inflammatory bowel disease and the gut microbiota.Clinical and translational medicine · 2025Review
- Treg and intestinal myofibroblasts-derived Amphiregulin induced by TGF-β mediates intestinal fibrosis in Crohn's disease.Journal of translational medicine · 2025Article
- [Cimifugin ameliorates Crohn's disease-like colitis in mice by modulating Th-cell immune balanceNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025Article
- Opportunities and challenges harnessing antigen-specific CD4+ regulatory T cells in inflammatory bowel disease.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 3 countries.
Funding
Abstract
BACKGROUND &
aimsThe incidence of Crohn's disease (CD) continues to increase worldwide. The contribution of CD4
methodsWe performed single-cell RNA-sequencing in CD4
resultsWe identified 5 distinct FOXP3
conclusionsWe identified a novel, proinflammatory FOXP3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.